Encainide
Back to searchMolecule Structure
Scientific Name
Encainide
Description of the Drug
Encainide is a voltage-gated sodium channel blocker used for management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia, that is no longer used due to proarrhythmic adverse effects.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01228
http://www.drugbank.ca/drugs/DB01228
Brand Name(s)
Not Available
Company Owner(s)
Not Available
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium channel alpha subunit | PROTEIN FAMILY | BLOCKER | CHEMBL2331043 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL94346 | |
| Human Metabolome Database | HMDB0015359 | |
| DrugBank | DB01228 | |
| PubChem: Thomson Pharma | 15373859 | |
| PubChem | 48041 | |
| Nikkaji | J1.621.570H | |
| EPA CompTox Dashboard | DTXSID0022983 | |
| DrugCentral | 1007 | |
| ChemicalBook | CB0969673 | |
| rxnorm | ENCAINIDE HYDROCHLORIDE | ENCAINIDE |
| PubChem: Drugs of the Future | 12012630 | |
| KEGG Ligand | C06978 | |
| ChEBI | 4788 |
